Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,229 public trials 1,177 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Active, Not Recruiting

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +13 more
Locations
  • Univ. of Cali. San Francisco Medical Center San Francisco, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Cancer Specialists of North Florida (Cbo) Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 30 locations
View Trial Details
Active, Not Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC

NCT04526782

Conditions
BRAF V600E, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
Locations
  • Annemasse - CH Ambilly, France
  • Angers - CHU Angers, France
  • Avignon - Institut Sainte-Catherine Avignon, France
  • Bordeaux - Institut Bergonié Bordeaux, France
View all 36 locations
View Trial Details
Active, Not Recruiting

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +43 more
Locations
  • HonorHealth Research and Innovation Institute Scottsdale, Arizona, United States
  • University of California San Diego San Diego, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • Memorial Healthcare System Hollywood, Florida, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

NCT05200481

Conditions
ALK Gene Mutation, Bronchial Neoplasms, Carcinoma, Bronchogenic, +9 more
Locations
  • CHU d'Angers Angers, France
  • CHU Besançon - Hôpital J. MINJOZ Besançon, France
  • Hôpital APHP Ambroise Paré Boulogne, France
  • Hospices Civils de Lyon - Hôpital Louis Pradel Bron, France
View all 29 locations
View Trial Details
Active, Not Recruiting

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371

Conditions
Adnexal Diseases, Advanced Solid Tumor Historically Known for High EphA2 Expression, Breast Diseases, +49 more
Locations
  • California Cancer Associates for Research and Excellence, Inc. Encinitas, California, United States
  • University of California - Irvine Medical Center Orange, California, United States
  • Sarah Cannon Research Institute at HealthONE Denver, Colorado, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
View all 28 locations
View Trial Details
Active, Not Recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

NCT06212752

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Fujita Health University ( Site 4406) Toyoake, Aichi-ken, Japan
  • Kurume University Hospital ( Site 4412) Kurume, Fukuoka, Japan
  • Gunma Prefectural Cancer Center ( Site 4416) Otashi, Gunma, Japan
  • National Hospital Organization Hokkaido Cancer Center ( Site 4415) Sapporo, Hokkaido, Japan
View all 18 locations
View Trial Details
Active, Not Recruiting

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

NCT02955290

Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Squamous Non-Small Cell Lung Carcinoma, Bronchial Neoplasms, +29 more
Locations
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • St. Francis Hospital Roslyn, New York, United States
  • Good Samaritan Hospital West Islip, New York, United States
View Trial Details
Active, Not Recruiting

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

NCT03672773

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +9 more
Locations
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • St. Joseph Heritage Healthcare Fullerton, California, United States
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Orlando Health, Inc. d/b/a Orlando Health UF Health Center Orlando, Florida, United States
View Trial Details

Related conditions